![RSV positivity associated with reduced serious bacterial infection risk [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/09/800px-Respiratory_syncytial_virus_01-350x250.jpg)
RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
1. In this phase 2a study, the RSVpreF vaccine was effective against symptomatic respiratory syncytial virus (RSV) infection as compared ...
Tag: vaccine
Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males
1. The highest incidence of myocarditis or pericarditis was seen after the second dose of Moderna (mRNA-1273) in young men ...
The Moderna mRNA vaccine prevents COVID-19 infection in adolescents
1. The Moderna mRNA vaccine significantly decreased the risk of contracting coronavirus disease 2019 (COVID-19) in adolescents. 2. For adolescents ...
Plant-based CoVLP+AS03 vaccine protects against COVID-19 infection
1. Two doses of the CoVLP+AS03 vaccine reduced the risk of contracting coronavirus disease 2019 (COVID-19) and infection severity compared ...
Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women
1. The prefusion F protein of RSV (RSVpreF) vaccine produces neutralizing antibodies against RSV in both the serum of the ...
Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months
1. EV71vac showed a vaccine efficacy of 96.8% against EV71-associated diseases. 2. Majority of adverse events were mild and self-limited ...
DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older
1. Seroconversion at 84 days was greater in the ZyCoV-D group compared to placebo. 2. The occurrence of adverse events ...
AD26.COV2.S vaccine provides protection against Covid-19
1. The AD26.COV2.S vaccine provided protection against moderate to severe-critical Covid-19. 2. The AD26.COV2.S vaccine provided protection against severe Covid-19 ...
COVID-19 infection risk increases as the time elapsed since receiving a 2nd dose of Pfizer vaccine increases
1. In a retrospective cohort study, compared to the risk in the initial 90 days after receiving a 2nd dose, ...
No Difference in Antibody or Humoral Responses Among Kidney Transplant Recipients Vaccinated with a 3rd Dose of mRNA or Adenovirus Vector Vaccine
1. In kidney transplant recipients (KTRs) who had no antibody response after a 2nd mRNA COVID-19 vaccine dose, there was ...